Drug Trial Radar · NCT01721408
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Last checked: Nov 20, 2026Latest source record: Apr 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
470
Actual
Start
Nov 2012
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a comparative study of the efficacy and safety of tigecycline to imipenem/cilastatin in hospitalized patients with a complicated intra-abdominal infection.
Conditions
- Intra-abdominal Infection
Interventions
TigecyclineDrug
every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
Imipenem/cilastatinDrug
every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) PopulationTime frame: Day 3, Day 14 or last day of therapy (treatment duration was at least 5 days and up to 14 days), and TOC (14-21 days after the last dose of therapy)
- Clinical Response at the TOC Assessment Within the Modified Intent-to-Treat (mITT) PopulationTime frame: Day 3, Day 14 or last day of therapy (treatment duration was at least 5 days and up to 14 days), and TOC (14-21 days after the last dose of therapy)
Locations
47 sites in 1 country. Site status is shown where the registry gives one.
China Meitan General Hospital/General Surgery Department
Beijing, China
Department of General Surgery,Beijing Shijitan Hospital,Capital Medical University
Beijing, China
Navy General Hospital PLA China/Genaral Surgery Department
Beijing, China
Peking University Third Hospital
Beijing, China
Department of General Surgery, Peking Union Medical College Hospital
Beijing, China
Institute of Antibiotics, Hua Shan Hospital, Fudan University
Shanghai, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Zhongshan Hospital Affiliated to Fudan University Qingpu Branch, Department of Surgery,
Shanghai, China
Tianjin Union Medical Center
Tianjin, China
Department of General Surgery, Tianjin Medical University General Hospital
Tianjin, China
Tianjin Nankai Hospital
Tianjin, China
Anqing City Hospital
Anqing, Anhui, China
Department of Hepatobiliary Surgery, Peking University People's Hospital
Xicheng District, Beijing Municipality, China
Zhongshan Hospital Xiamen University
Xiamen, Fujian, China
Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, Fujian, China
Department of General Surgery, the First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of JiNan University/General Surgery
Guangzhou, Guangdong, China
The First Hospital of Shantou University School of Medicine
Shantou, Guangdong, China
Shenzhen Second People's Hosptial/Department of hepatobiliary surgery
Shenzhen, Guangdong, China
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
HaiKou Municipal People's Hospital
Haikou, Hainan, China
Hainan Provincial People's Hospital
Haikou, Hainan, China
The Third People's Hospital of Hainan Province/department of general surgery
Sanya, Hainan, China
Tongji Medical College, Huazhong University of Science and Technology, The Central Hospital of Wuhan
Wuhan, Hubei, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University/Intensive Care Unit
Wuhan, Hubei, China
Xiangya Hospital Central-South University/General Surgery
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University/Department of General Surgery
Changsha, Hunan, China
The Third Hospital of Changsha/Department of Surgery
Changsha, Hunan, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
The Affiliated Jiangyin Hospital of Southeast University Medical College, General Surgery Department
Jiangyin, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Yangzhou No.1 People's Hospital
Yangzhou, Jiangsu, China
Jilin Province People's Hospital
Changchun, Jilin, China
The First Hospital of Jilin University/Surgery
Changchun, Jilin, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Qinghai Provincial People's Hospital
Xining, Qinghai, China
Binzhou Medical University Hospital
Binzhou, Shandong, China
Shanghai Fengxian District Central Hospital, Department of Surgery
Shanghai, Shanghai Municipality, China
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.